Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1632568 | 0.90 | HRH3 (0.43) | HRH3MAP4K1CDK4CCND1CDK6 | |
| SCHEMBL1634962 | 0.88 | HRH3 (0.41) | HRH3MAP4K1CDK4CCND1CDK6 | |
| SCHEMBL1632199 | 0.88 | MAP4K1 (0.44) | HRH3MAP4K1SCN9ACDK4CCND1 | |
| SCHEMBL1633226 | 0.88 | MAP4K1 (0.51) | HRH3MAP4K1SCN9ACDK4CCND1 | |
| SCHEMBL1634487 | 0.87 | HRH3 (0.43) | HRH3MAP4K1SCN9ACDK4CCND1 | |
| SCHEMBL1633471 | 0.87 | CDK2 (0.47) | HRH3MAP4K1CDK4CCND1CDK6 | |
| SCHEMBL1634242 | 0.86 | HRH3 (0.44) | HRH3MAP4K1CDK4CCND1CDK6 | |
| SCHEMBL1633930 | 0.86 | HRH3 (0.43) | HRH3MAP4K1SCN9ACDK4CCND1 | |
| SCHEMBL1632946 | 0.86 | IKBKB (0.45) | HRH3MAP4K1CDK4CDK6 | |
| SCHEMBL1633767 | 0.85 | HRH3 (0.53) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | HRH3 3514/4885MAP4K1 48/4885SCN9A 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.